Literature DB >> 17022220

Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.

Helena Uusijärvi1, Peter Bernhardt, Thomas Ericsson, Eva Forssell-Aronsson.   

Abstract

Various radionuclides have been proposed for systemic tumor therapy. However, in most dosimetric analysis of proposed radionuclides the charged particles are taken into consideration while the potential photons are ignored. The photons will cause undesirable irradiation of normal tissue, and increase the probability of toxicity in, e.g., the bone marrow. The aim of this study was to investigate the dosimetric properties according to particle range, photon emission, and subcellular radionuclide distribution, of a selection of radionuclides used or proposed for radionuclide therapy, and to investigate the possibility of dividing radionuclides into groups according to their dosimetric properties. The absorbed dose rate to the tumors divided by the absorbed dose rate to the normal tissue (TND) was estimated for different tumor sizes in a mathematical model of the human body. The body was simulated as a 70-kg ellipsoid and the tumors as spheres of different sizes (1 ng-100 g). The radionuclides were either assumed to be uniformly distributed throughout the entire tumor and normal tissue, or located in the nucleus or the cytoplasm of the tumor cells and on the cell membrane of the normal cells. Fifty-nine radionuclides were studied together with monoenergetic electrons, positrons, and alpha particles. The tumor and normal tissue were assumed to be of water density. The activity concentration ratio between the tumor and normal tissue was assumed to be 25. The radionuclides emitting low-energy electrons combined with a low photon contribution, and the alpha emitters showed high TND values for most tumor sizes. Electrons with higher energy gave reduced TND values for small tumors, while a higher photon contribution reduced the TND values for large tumors. Radionuclides with high photon contributions showed low TND value for all tumor sizes studied. The radionuclides studied could be divided into four main groups according to their TND values: beta emitters, Auger electron emitters, photon emitters, and alpha emitters. The TND values of the beta emitters were not affected by the subcellular distribution of the radionuclide. The TND values of the Auger electron emitters were affected by the subcellular radionuclide distribution. The photon emitters showed low TND values that were only slightly affected by the subcellular radionuclide distribution. The alpha emitters showed high TND values that were only slightly affected by the subcellular radionuclide distribution. This dosimetric characterization of radionuclides may be valuable in choosing the appropriate radionuclides for specific therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17022220     DOI: 10.1118/1.2229428

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  12 in total

1.  A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy.

Authors:  Robert F Hobbs; Sébastien Baechler; De-Xue Fu; Caroline Esaias; Martin G Pomper; Richard F Ambinder; George Sgouros
Journal:  Med Phys       Date:  2011-06       Impact factor: 4.071

2.  Recombinant α1-Microglobulin Is a Potential Kidney Protector in 177Lu-Octreotate Treatment of Neuroendocrine Tumors.

Authors:  Charlotte K Andersson; Emman Shubbar; Emil Schüler; Bo Åkerström; Magnus Gram; Eva B Forssell-Aronsson
Journal:  J Nucl Med       Date:  2019-03-29       Impact factor: 10.057

3.  Cyclotron production and radiochemical separation of 55Co and 58mCo from 54Fe, 58Ni and 57Fe targets.

Authors:  H F Valdovinos; R Hernandez; S Graves; P A Ellison; T E Barnhart; C P Theuer; J W Engle; W Cai; R J Nickles
Journal:  Appl Radiat Isot       Date:  2017-09-06       Impact factor: 1.513

4.  Pharmacokinetics and dosimetry of (111)In/(188)Re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models.

Authors:  Yi-Yu Lin; Chih-Hsien Chang; Jia-Je Li; Michael G Stabin; Ya-Jen Chang; Liang-Cheng Chen; Ming-Hsien Lin; Yun-Long Tseng; Wuu-Jyh Lin; Te-Wei Lee; Gann Ting; Cheng Allen Chang; Fu-Du Chen; Hsin-Ell Wang
Journal:  Cancer Biother Radiopharm       Date:  2011-06-28       Impact factor: 3.099

5.  Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.

Authors:  Cristina Müller; Josefine Reber; Stephanie Haller; Holger Dorrer; Peter Bernhardt; Konstantin Zhernosekov; Andreas Türler; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-08       Impact factor: 9.236

Review 6.  Auger processes in the 21st century.

Authors:  Roger W Howell
Journal:  Int J Radiat Biol       Date:  2008-12       Impact factor: 2.694

7.  Relationship of In Vitro Toxicity of Technetium-99m to Subcellular Localisation and Absorbed Dose.

Authors:  Ines M Costa; Noor Siksek; Alessia Volpe; Francis Man; Katarzyna M Osytek; Elise Verger; Giuseppe Schettino; Gilbert O Fruhwirth; Samantha Y A Terry
Journal:  Int J Mol Sci       Date:  2021-12-15       Impact factor: 5.923

8.  Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate.

Authors:  Stephanie Haller; Giovanni Pellegrini; Christiaan Vermeulen; Nicholas P van der Meulen; Ulli Köster; Peter Bernhardt; Roger Schibli; Cristina Müller
Journal:  EJNMMI Res       Date:  2016-02-09       Impact factor: 3.138

9.  Tumor burden talks in cancer treatment with PEGylated liposomal drugs.

Authors:  Yi-Yu Lin; Hao-Wen Kao; Jia-Je Li; Jeng-Jong Hwang; Yun-Long Tseng; Wuu-Jyh Lin; Ming-Hsien Lin; Gann Ting; Hsin-Ell Wang
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

10.  Dosimetric analysis of (123)I, (125)I and (131)I in thyroid follicle models.

Authors:  Anders Josefsson; Eva Forssell-Aronsson
Journal:  EJNMMI Res       Date:  2014-06-11       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.